Ascendis Pharma (ASND) said late Wednesday its board has allocated $25 million to fund a share buyback program and the net settlement of certain restricted stock units, or RSUs.
The buyback program authorizes the repurchase from time to time of up to about $18.3 million of American depositary shares.
The company also plans to apply a net settlement of tax-withholding obligations related to certain RSUs for about $9 million in cash.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.